New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For CI;WCG;HNT;MOH;UNH;CVH;WLP;AGP;CNC;HS;HUM;AET;MDT;BSX;STJ From The Last 14 Days
Check below for free stories on CI;WCG;HNT;MOH;UNH;CVH;WLP;AGP;CNC;HS;HUM;AET;MDT;BSX;STJ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | all recent news | >>
April 22, 2014
06:08 EDTCNCCentene reports Q1 EPS ex-items 79c, consensus 44c
Reports Q1 revenue $3.46B, consensus $3.25B. Reports diluted EPS of 79c excluding 16c of net cost associated with the health insurer fee and 6c of U.S. Medical Management acquisition transaction costs. Michael F. Neidorff, Centene's chairman and CEO, stated, "The company continues to diversify and add capabilities to the business, driving significant revenue and earnings growth year over year in Q1. Our guidance increase is driven by strong Q1 results across all metrics providing positive momentum for the remainder of the year."
April 21, 2014
18:47 EDTMDTInjunction delay 'temporary victory' for Medtronic, says Wells Fargo
Subscribe for More Information
18:20 EDTMDTEdwards Lifesciences comments on U.S. Appeals Court order
Edwards Lifesciences (EW) announced that the U.S. Court of Appeals for the Federal Circuit issued a stay for the preliminary injunction that was ordered on April 11 to limit the sale of Medtronic's (MDT) CoreValve system in the United States. According to the court's two-to-one decision, the injunction has been placed on hold "pending further notice." "We have always made every effort to ensure patients receive the treatment they need and will continue to seek a durable solution that benefits physicians and their patients. We're proud of the track record and large amount of clinical data supporting the performance of the SAPIEN family of valves, making them the preferred choice for doctors treating their patients around the world," said Michael A. Mussallem, Edwards' chairman and CEO. The order postpones the implementation of the preliminary injunction. It does not reverse the federal jury's finding of Medtronic's willful infringement, for which all appeals have been exhausted, and does not affect the determination of additional damages.
16:40 EDTMDTMedtronic confirms stay in case with Edwards regarding CoreValve granted
Subscribe for More Information
15:55 EDTMDTMedtronic motion for stay in case with Edwards granted, Bloomberg reports
Subscribe for More Information
15:42 EDTMDTLeerink's medical devices analyst holds an analyst/industry conference call
Medical Devices Analyst Antalffy discusses the litigation landscape and the next steps and potential outcomes for Edwards Lifesciences and Medtronic on an Analyst/Industry conference call to be held on April 23 at 2 pm.
09:09 EDTMDTMedtronic reports court to expedite appeal in Edwards Lifesciences case
Subscribe for More Information
07:21 EDTMDTFDA Pediatric Advisory Committee to hold a meeting
The Committee discusses pediatric-focused safety reviews including MDT's Activa Dystonia Therapy, (BAX's Advate and Tisseel, NVS' Famvir, Tibotec's (JNJ subsidiary) Intelence, UCB Pharma's Keppra, MRK's Maxalt, BAYRY's Natazia, Digestive Care's Pertzye, JNJ's Prezista, BMY's Reyataz, SNY's Sklice, PFE's Torisel, Aptalis' Ultresa, and GILD's Viread in a meeting being held in Bethesda, Maryland on April 21 at 8 am. Webcast Link
April 17, 2014
12:53 EDTAET, WLP, UNHOn The Fly: Midday Wrap
Subscribe for More Information
10:56 EDTUNHUnitedHealth backs FY14 EPS, revenue guidance
UnitedHealth earlier backed its FY14 EPS view of $5.40-$5.60, consensus $5.59, and its FY14 revenue view of $128B-$129B, consensus $128.94B.
10:51 EDTWLP, AET, HUM, HNT, UNHHealth insurers slide after UnitedHealth results, cautious comments
Shares of a number of health insurers are falling after the largest company in the sector, UnitedHealth (UNH), reported slightly higher than expected first quarter profit but lower than expected revenue. WHAT'S NEW: UnitedHealth's first quarter earnings per share came in at $1.10, versus the consensus outlook of $1.09. The insurer reported revenue of $31.71B, compared with the consensus outlook of $31.99B. Taxes levied by the Affordable Care Act and weak funding of Medicare Advantage by the government weighed on UnitedHealth's earnings, the company stated. Also pushing down the company's earnings was "a very expensive," new Hepatitis C therapy, UnitedHealth stated on its earnings conference call. Hepatitis C treatments cost UnitedHealth hundreds of millions of dollars in the first quarter, the company stated, though it also noted that demand for the treatments should drop going forward as initial pent-up demand for them starts to decline. The company indicated that it was looking to be reimbursed by states for the money it is spending on hepatitis vaccines for Medicaid patients. Meanwhile, UnitedHealth reiterated its fiscal 2014 EPS guidance of $5.40-$5.60 and its fiscal 2014 revenue guidance of $128B-$129B. PRICE ACTION: In mid-morning trading, UnitedHealth sank 3.7% to $75.31. Other health insurers also declined, with WellPoint (WLP) dropping 4% to $91.89, Aetna (AET) falling 3.3% to $67.54, Humana (HUM) declining 2.25% to $106.35, and Health Net (HNT) sliding 1% to $31.74.
08:00 EDTSTJSt. Jude Medical price target lowered to $47 from $51 at Canaccord
Subscribe for More Information
06:02 EDTUNHUnitedHealth:Q1 negatively impacted by ACA taxes, ACA provisions, sequestration
Subscribe for More Information
06:02 EDTUNHUnitedHealth reports Q1 Medical Care Ratio 82.5%
Reports Q1 Optum revenue $11.2B
06:01 EDTUNHUnitedHealth reports Q1 EPS $1.10, consensus $1.09
Subscribe for More Information
April 16, 2014
17:53 EDTMDTEdwards says not looking for complete ban of Medtronic valve, Bloomberg says
Subscribe for More Information
15:39 EDTSTJ, BSXBoston Scientific CRT-D approval neutral for St. Jude, says Wells Fargo
Subscribe for More Information
15:17 EDTUNHNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include General Electric (GE), consensus 32c; Philip Morris (PM), consensus $1.16; Schlumberger (SLB), consensus $1.20; PepsiCo (PEP), consensus 75c; Union Pacific (UNP), consensus $2.37; UnitedHealth (UNH), consensus $1.09; Honeywell (HON), consensus $1.26; Goldman Sachs (GS), consensus $3.44; du Pont (DD), consensus $1.59; Morgan Stanley (MS), consensus 60c; Danaher (DHR), consensus 80c; BlackRock (BLK), consensus $4.14; Blackstone (BX), consensus 55c; Chipotle Mexican Grill (CMG), consensus $2.86; Mattel (MAT), consensus 9c; Snap-on (SNA), consensus $1.54; AutoNation (AN), consensus 74c.
12:01 EDTHUMHumana, Dignity Health sign agreement
Subscribe for More Information
10:08 EDTAET, WLP, HUM, UNHUnitedHealth retreats after Citi cuts rating on shares
Subscribe for More Information
<< 1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use